ASH 2019 Annual Meeting Highlights in Multiple Myeloma
Release Date: January 06, 2020
Expiration Date: January 06, 2021
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
In this activity, key opinion leaders present important highlights of several significant scientific updates in multiple myeloma (MM) presented at the 2019 American Society of Hematology (ASH) Annual Meeting. In this activity, experts share their insights on a variety of abstracts covering topics including, but not limited to: CAR-T cell therapy for relapsed/refractory multiple myeloma (RRMM), venetoclax in combination with bortezomib and dexamethasone in patients with RRMM, results from the phase 3 CANDOR study, and updates of the phase 3 POLLUX study.
This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, nurses, pharmacists and other allied healthcare professionals who provide care to patients with multiple myeloma.
Upon completion of this educational activity, participants should be able to:
- Summarize the efficacy and safety data from clinical trials investigating treatment approaches across the multiple myeloma disease lifecycle, including for smoldering MM, NDMM, RRMM, and maintenance
- Outline clinical trials and recent advances in the management of disease- and treatment-related conditions in MM, including skeletal-related conditions and VTEs
- Describe expert faculty perspectives on clinical trial data for emerging novel approaches to the treatment of MM, including CAR T-cell therapies, bi-specific antibodies, and antibody-drug conjugates
- Updated Analysis of BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone, in Patients with RRMM – Shaji K. Kumar, MD, FACP
- Predictive Biomarkers in the BELLINI Study: t(11;14) and High BCL2 Expression – Shaji K. Kumar, MD, FACP
- Primary Results from the Phase 3 Tourmaline-AL1 Trial of Ixazomib-Dexamethasone Versus Physician's Choice of Therapy in Patients with RR Primary Systemic Amyloidosis – Shaji K. Kumar, MD, FACP
- Four-Year Follow-up of the Phase 3 POLLUX Study of Dara Plus Len-Dex Versus Len-Dex Alone in RRMM – Sagar Lonial, MD, FACP
- Depth of Response to Dara-RVd Improves Over Time in Patients with Transplant-Eligible Newly Diagnosed MM: GRIFFIN Study Update – Sagar Lonial, MD, FACP
- Findings from a Phase 1 Study of PF-06863135, a B-cell Maturation, CD3 Bispecific Antibody, in Patients with RRMM – Noopur Raje, MD
- Updated Results from an Ongoing Phase 1 Clinical Study of bb21217 Anti-BCMA CAR T-cell Therapy – Noopur Raje, MD
- Phase 3 Study of Subcutaneous Versus Intravenous Daratumumab Administration in Patients with RRMM: COLUMBA Updates – Saad Z. Usmani, MD, FACP
- Kd-Dara Versus Kd for the Treatment of Patients with RRMM: Primary Analysis Results from the Phase 3 CANDOR Study – Saad Z. Usmani, MD, FACP
- Selinexor, Pomalidomide, and Dexamethasone in Patients with RRMM – Saad Z. Usmani, MD, FACP
Instructions for Participation and Credit
This activity is eligible for credit through January 6, 2021. After this date, this activity will expire and no further credit will be awarded.
- Read the target audience, learning objectives, and faculty disclosures.
- You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
- Complete the educational content as designed.
- Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
- Complete the activity evaluation survey to provide feedback and information useful for future programming.
- Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Shaji K. Kumar, MD, FACP
Professor of Medicine
Clinical Research Office
Mayo Clinic Cancer Center
Dr. Shaji Kumar received his medical degree from All India Institute of Medical Sciences in New Delhi, India. His postdoctoral training included a residency in internal medicine from the All India Institute of Medical Sciences, followed by a residency in internal medicine and a fellowship in hematology/oncology at the Mayo Graduate School of Medicine in Rochester, Minnesota. Dr. Kumar is a Consultant in the Division of Hematology and Professor of Medicine at Mayo Clinic Cancer Center in Rochester, Minnesota. He serves as Medical Director for the Mayo Clinic Cancer Center Clinical Research Office and Vice Chair for research in the Department of Medicine, Mayo Clinic.
Dr. Kumar serves as Co-Chair of the NCI Myeloma Steering Committee as Chair of the NCCN Multiple Myeloma Guidelines Panel. His research focuses on the development of novel drugs and drug combinations for the treatment of myeloma. His laboratory focuses on understanding the role of bone marrow microenvironment in the development and progression of myeloma.
Sagar Lonial, MD, FACP
Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Dr. Sagar Lonial earned his medical degree from the University of Louisville School of Medicine. He completed his internship and residency at Baylor College of Medicine in Houston, Texas, followed by a fellowship in hematology/oncology at Emory University School of Medicine in Atlanta, Georgia. He is the Department Chair for Hematology and Medical Oncology at Emory University.
Dr. Lonial serves as Vice Chair of the Myeloma Committee in the Eastern Cooperative Oncology Group and as Chair of the Steering Committee for the Multiple Myeloma Research Consortium. Additionally, he is on the Board of Directors for the International Myeloma Society and on the Scientific Advisory Board for the International Myeloma Foundation. Dr. Lonial is the myeloma editor for Clinical Lymphoma and Myeloma and is on the editorial board for the Journal of Clinical Oncology. He is also an ad hoc reviewer for Blood, Cancer Research, Clinical Cancer Research, Haematologica, Leukemia, and other journals, and has authored or co-authored over 200 papers and abstracts.
Dr. Lonial has worked in the field of immunotherapy and cancer, and has spent time developing the B-cell malignancy program with respect to novel targeted agents in laboratory models as well as early clinical trials. His previous laboratory work has focused on evaluating the impact of purified dendritic cell subsets on the nature of immune responses against antigen. Most recently, Dr. Lonial has focused on combinations of novel agents as therapy for myeloma and lymphoma, particularly evaluating combinations that may result in synergistic inhibition of the PI3-K/Akt pathway and the role of 14-3-3 in proteasome function.
Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director, Center for Multiple Myeloma
Massachusetts General Hospital
Dr. Noopur Raje received her medical degree from B.J. Medical College, Pune University in India. She trained in internal medicine at Massachusetts General Hospital (MGH), and subsequently completed a fellowship in hematology and medical oncology in the joint Mass General-Brigham & Women’s-Dana-Farber program. She is a Professor of Medicine at Harvard Medical School and the Rita M. Kelley Chair in Oncology at MGH.
Dr. Raje is a physician scientist with a focus on the development of innovative therapies for multiple myeloma. As Director of the Center for Multiple Myeloma at the MGH Cancer Center, she leads a dedicated clinical team engaged in investigator-initiated, multicenter national and international clinical trials, all aimed at developing new promising therapies for this disease. She also leads translational efforts at MGH with her laboratory's efforts focused on identifying cellular signaling pathways that contribute to the survival and proliferation of myeloma cells in the bone environment, and whose targeting may result in improved therapeutic outcomes. Dr. Raje is the recipient of numerous awards including the Multiple Myeloma Senior Research Award, The Leukemia and Lymphoma Society Clinical Scholar Award and the Claflin Distinguished Scholar Award.
Saad Z. Usmani, MD, FACP
Division Chief, Plasma Cell Disorders Division
Director, Clinical Research in Hematologic Malignancies
Department of Hematologic Oncology & Blood Disorders
Levine Cancer Institute
Charlotte, North Carolina
Dr. Saad Usmani received his medical education at Allama Iqbal Medical College Lahore, Pakistan. He completed a residency in internal medicine at Sinai-Grace Hospital/Wayne State University in Detroit, Michigan, and a fellowship in hematology and oncology at the University of Connecticut Health Center in Farmington, Connecticut. Dr. Usmani joined the Levine Cancer Institute faculty in July 2013; he also currently holds an academic appointment as Clinical Professor of Medicine at the University of North Carolina-Chapel Hill School of Medicine. Previously, Dr. Usmani served as an Assistant Professor of Medicine at the University of Arkansas for Medical Sciences in Little Rock, Arkansas, and Director of Developmental Therapeutics at the Myeloma Institute for Research & Therapy.
Dr. Usmani is board certified in internal medicine, medical oncology, and hematology, and is a fellow of the American College of Physicians. He holds membership in several professional societies, including the International Myeloma Working Group (IMWG), SWOG Myeloma Committee, American Society of Hematology (ASH), American Society of Clinical Oncology (ASCO), and the American Society of Bone Marrow Transplantation (ASBMT). Dr. Usmani has served as the Track Leader on the ASCO Scientific Committee on Lymphoma and Plasma Cell Disorders, and he is a member of the ASH Committee on Plasma Cell Neoplasia and the National Cancer Institute Myeloma Steering Committee. He is on the editorial review board of numerous medical journals, and has authored/co-authored more than 130 peer-reviewed research manuscripts and 190 abstracts at national and international meetings. Active in clinical and translational research, Dr. Usmani’s research interests focus on plasma cell disorders—in particular, high-risk multiple myeloma.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-002-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 20-002-115
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Shaji Kumar has received honoraria related to speakers’ bureau and formal advisory activities from AbbVie Inc., Adaptive Biotechnologies, Celgene Corporation, Janssen Pharmaceuticals, Inc., Kite Pharma, AstraZeneca (formerly MedImmune, LLC), Oncopeptides AB, and Takeda Oncology. He has received research support for Mayo Clinic Cancer Center clinical trials from AbbVie, Celgene, Janssen, F. Hoffmann-La Roche Ltd, Kite, AstraZeneca, Merck & Co., Inc., Novartis AG, Sanofi, and Takeda.
Dr. Sagar Lonial has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novartis AG, and Takeda Oncology.
Dr. Shaji Kumar has received honoraria as a consultant from AbbVie Inc., Amgen Inc., Celgene Corporation, Genentech, Inc., Janssen Pharmaceuticals, Inc., Kite Pharma, MedImmune, LLC, Merck & Co., Inc., Oncopeptides AB, and Takeda Oncology. He has received grant support related to research activities from AbbVie, Amgen, Bristol-Myers Squibb Company, Celgene, Janssen, F. Hoffmann-La Roche Ltd, Genentech, Kite, MedImmune, Merck, Novartis AG, Sanofi, and Takeda.
Dr. Noopur Raje has received honoraria as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., and Takeda Oncology. She has received grant support related to research activities from AstraZeneca. Dr. Raje has also received honoraria for continuing education from Research to Practice and from Medscape.
Dr. Saad Usmani has received honoraria related to speakers’ bureau activities from Amgen Inc., Celgene Corporation, Janssen Pharmaceuticals, Sanofi, and Takeda Oncology, as well as consultant fees from Amgen, Bristol-Myers Squibb Company, Celgene, GlaxoSmithKline plc, Janssen, Merck & Co., Inc., Skyline Diagnostics B.V., and Takeda. He has received grant support related to research activities from Amgen, Array BioPharma, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Merck, Pharmacyclics, Inc., Sanofi, Skyline Diagnostics, Seattle Genetics, Inc., and Takeda.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Andrea Mathis, Project Manager, Wilma Guerra, Program Director, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Celgene Corporation.
©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.